Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin and Gemcitabine in Second-Line Advanced NSCLC
NCT00305786Phase 2Completed
- Sponsor
- University of Miami
- Start
- Aug 2005
- Primary completion
- Dec 2007
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and oxaliplatin in non-small cell lung cancer (NSCLC), sponsored by University of Miami. Primary endpoint: Objective Response Rate. Started Aug 2005; status: completed.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00305786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00305786.